ClinicalTrials.gg
CompletedNCT01070303CLASSICIIUpdated Apr 11, 2011Results posted

Remission in Subjects With Crohn's Disease, Open Label Extension

A Phase 3 interventional study of Adalimumab 40 mg eow or ew in Crohn's Disease, sponsored by Abbott. Completed at 43 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-11.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
177
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
18th of 42
177 · median 143
Started
2002
with 2 others
Phase 3
22 of 42
none open now
Registered
16th of 42
by date
Lead sponsor
13 of 42
Abbott

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 18th largest by enrollment, is one of 3 that started in 2002, is one of 22 in phase 3, and was the 16th registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

The objectives were: (1) To demonstrate the efficacy of adalimumab in the long-term maintenance of clinical remission in participants with Crohn's disease; and (2) To delineate the long-term safety of adalimumab when administered to participants with Crohn's disease.

Read the detailed description

Study M02-433 was designed to evaluate the efficacy and safety of adalimumab in the maintenance of clinical remission in patients with Crohn's disease (CD). The study consisted of 2 phases: 1. a 1-year phase (Week 0 to Week 56) (NCT00055497) that consisted of a randomized, double-blind, placebo-controlled portion with a concomitant open label (OL) portion, and 2. a long-term open-label extension (OLE) phase (NCT01070303) that lasted 264 additional weeks (Week 56 to Week 320).

Participants who completed the lead-in study NCT00055523, were eligible to participate in the rollover study, NCT00055497. 176 participants were documented as having completed Year 1 (NCT00055497); however, 177 participants were still receiving study drug and were evaluated at Week 56 of NCT00055497; these participants are included in the OLE data (NCT01070303).

At Week 4 of NCT00055497, participants who demonstrated clinical remission (defined as a Crohn's Disease Activity Index [CDAI] score \<150 points) at Baseline of NCT00055497 and who remained in clinical remission at Week 4 ("Remitters") were randomized to receive 1 of 3 blinded treatments: placebo, adalimumab 40 mg every other week (eow), or adalimumab 40 mg every week (ew). Participants who did not demonstrate clinical remission at Baseline of NCT00055497 or who were no longer in clinical remission at Week 4 of NCT00055497 ("Non-remitters") were assigned to receive OL adalimumab 40 mg eow. All study drug (placebo and active) was administered by subcutaneous (SC) injection.

At any time during Study NCT00055497, a participant receiving blinded study drug who developed a disease flare could be switched to OL adalimumab 40 mg eow. A participant receiving OL adalimumab 40 mg SC eow who developed a flare or was a non-responders could have had his/her dose increased to 40 mg SC ew.

After 1 year (Week 56 of NCT00055497), patients who were still participating could continue in the OLE phase (NCT01070303). Participants who were receiving blinded study drug were switched to OL adalimumab 40 mg SC eow, and participants who were receiving OL study drug continued on their previous OL adalimumab dose (adalimumab 40 mg SC eow or ew).

Data are summarized for Remitters and Non-remitters, with the exception of data for primary reason for noncompletion. Summaries of primary reason for noncompletion were available only for all participants, not for Remitters and Non-remitters. Data are reported for Weeks 104, 152, 212, and 260 of Study M02-433, starting from Week 0 of NCT00055497; these weeks correspond to 1, 2, 3, and 4 years of participation in NCT01070303. Change from Baseline results (clinical response 70, clinical response 100, Inflammatory Bowel Disease Questionnaire, and fistula remission) are calculated from Baseline of the lead-in study (NCT00055523). Results on each assessment at each measurement time point are presented as individual outcome measures because different numbers of participants were evaluated at each time point (as observed analysis).

03

Conditions studied

  • Crohn's Disease

Keywords

  • HUMIRA
  • adalimumab
  • Inflammatory Bowel Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant had completed the Year 1 of Study M02-433 (NCT00055497)
  • Diagnosis of Crohn's disease
  • Willing and able to give

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of ulcerative colitis
  • Pregnancy or breastfeeding
  • Previous use of infliximab or other anti-TNF (tumor necrosing factor) antagonists
  • Previous history of active tuberculosis or listeria infection
  • Previous history of cancer other than successfully treated skin cancer
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
177 participants (actual)

Study arms

  • Experimental
    Adalimumab 40 mg every other week or every week

    Biological: Adalimumab 40 mg eow or ew

Interventions

  • Adalimumab 40 mg by subcutaneous injection every other week or every week

    Also known as: Adalimumab, Humira

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Clinical Remission (Crohn's Disease Activity Index[CDAI] <150 Points) at Week 104 of Study M02-433 (Starting From Week 0 of NCT00055497) (Through 1 Year of Participation in NCT01070303).

    Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.

    Time frame: Week 104

Secondary outcomes

  1. Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 152 (Through 2 Years of Participation in NCT01070303).

    Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.

    Time frame: Week 152

  2. Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 212 (Through 3 Years of Participation in NCT01070303).

    Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.

    Time frame: Week 212

  3. Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 260 (4 Years of Participation in NCT01070303).

    Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.

    Time frame: Week 260

  4. Number of Participants Achieving CR-100 at Week 104 (1 Year of Participation in NCT01070303)

    A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

    Time frame: From Baseline of lead-in study to Week 104

  5. Number of Participants Achieving CR-100 at Week 152 (2 Years of Participation in NCT01070303)

    A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

    Time frame: From Baseline of lead-in study to Week 152

  6. Number of Participants Achieving CR-100 at Week 212 (3 Years of Participation in NCT01070303)

    A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

    Time frame: From Baseline of lead-in study to Week 212

  7. Number of Participants Achieving CR-100 at Week 260 (4 Years of Participation in NCT01070303)

    A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

    Time frame: From Baseline of lead-in study to Week 260

  8. Number of Participants Achieving CR-70 at Week 104 (1 Year of Participation in NCT01070303)

    A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

    Time frame: Week 104

  9. Number of Participants Achieving CR-70 at Week 152 (2 Years of Participation in NCT01070303)

    A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

    Time frame: From Baseline of lead-in Study to Week 152

  10. Number of Participants Achieving CR-70 at Week 212 (3 Years of Participation in NCT01070303)

    CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

    Time frame: From Baseline of lead-in study to Week 212

  11. Number of Participants Achieving CR-70 at Week 260 (4 Years of Participation in NCT01070303)

    A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

    Time frame: From Baseline of lead-in study to Week 260

  12. Number of Participants Achieving Steroid-free Clinical Remission at Week 104 (1 Year of Participation in NCT01070303)

    Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.

    Time frame: From Baseline of lead-in study to Week 104

  13. Number of Achieving Steroid-free Clinical Remission at Week 152 (2 Years of Participation in NCT01070303)

    Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.

    Time frame: From Baseline of lead-in study to Week 152

  14. Number of Participants Achieving Steroid-free Clinical Remission at Week 212 (3 Years of Participation in NCT01070303)

    Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.

    Time frame: From Baseline of lead-in study to Week 212

  15. Number of Participants Achieving Steroid-free Clinical Remission at Week 260 (4 Years of Participation in NCT01070303)

    Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.

    Time frame: From Baseline of lead-in study to Week 260

  16. Number of Participants Achieving Steroid-free CR-100 at Week 104 (1 Year of Participation in NCT01070303)

    Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.

    Time frame: From Baseline of lead-in study to Week 104

  17. Number of Participants Achieving Steroid-free CR-100 at Week 152 (2 Years of Participation in NCT01070303)

    Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.

    Time frame: From Baseline of lead-in study to Week 152

  18. Number of Participants Achieving Steroid-free CR-100 at Week 212 (3 Years of Participation in NCT01070303)

    Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.

    Time frame: From Baseline of lead-in study to Week 212

  19. Number of Participants Achieving Steroid-free CR-100 at Week 260 (4 Years of Participation in NCT01070303)

    Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.

    Time frame: From Baseline of lead-in study to Week 260

  20. Changes in Inflammatory Bowel Disease Questionnaire (IBDQ) Scores

    IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period. It has 32 questions about bowel function and related symptoms, and their social and emotional impact. For each question, participants selected 1 of 7 responses, where 1=poor quality of life (e.g., feeling of fatigue "all of the time") and 7=good quality on the item (e.g., feeling of fatigue "none of the time"). IBDQ scores range from 32 to 224. Higher scores indicate better quality of life, and increases in IBDQ indicate improved overall quality of life.

    Time frame: Change from Baseline of lead-in study at Weeks 104, 152, 200, and 248

  21. Number of Participants Achieving Fistula Remission at Week 104 (1 Year of Participation in NCT01070303)

    A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.

    Time frame: From Baseline of lead-in study to Week 104

  22. Number of Participants Achieving Fistula Remission at Week 152 (2 Years of Participation in NCT01070303)

    A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.

    Time frame: From Baseline of lead-in study to Week 152

  23. Number of Participants Achieving Fistula Remission at Week 212 (3 Years of Participation in NCT01070303)

    A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.

    Time frame: From Baseline of lead-in study to Week 212

  24. Number of Participants Achieving Fistula Remission at Week 260 (Years of Participation in NCT01070303)

    A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.

    Time frame: From Baseline of lead-in study to Week 260

07

Results

Posted May 7, 2010

Participant flow

Participants who were still receiving study drug and were evaluated at Week 56 of Study M02-433 (NCT00055497) are included in the open-label extension (OLE) (NCT01070303). Participants entered NCT00055497 from a lead-in adalimumab induction therapy study (NCT00055523).

Participant flow — Overall Study
MilestoneAll Participants in Open-Label Extension of Study M02-433
Started177
Completed88
Not completed89
Withdrew: Adverse event39
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up9
Withdrew: Protocol violation0
Withdrew: Lack of efficacy2
Withdrew: Administrative reason1
Withdrew: Other18

Outcome measures

PrimaryNumber of Participants Achieving Clinical Remission (Crohn's Disease Activity Index[CDAI] <150 Points) at Week 104 of Study M02-433 (Starting From Week 0 of NCT00055497) (Through 1 Year of Participation in NCT01070303).

Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.

Time frame:
Week 104
Reported as:
Number · Participants
Number of Participants Achieving Clinical Remission (Crohn's Disease Activity Index[CDAI] <150 Points) at Week 104 of Study M02-433 (Starting From Week 0 of NCT00055497) (Through 1 Year of Participation in NCT01070303).
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Clinical Remission (Crohn's Disease Activity Index[CDAI] <150 Points) at Week 104 of Study M02-433 (Starting From Week 0 of NCT00055497) (Through 1 Year of Participation in NCT01070303).2971
SecondaryNumber of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 152 (Through 2 Years of Participation in NCT01070303).

Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.

Time frame:
Week 152
Reported as:
Number · Participants
Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 152 (Through 2 Years of Participation in NCT01070303).
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 152 (Through 2 Years of Participation in NCT01070303).2662
SecondaryNumber of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 212 (Through 3 Years of Participation in NCT01070303).

Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.

Time frame:
Week 212
Reported as:
Number · Participants
Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 212 (Through 3 Years of Participation in NCT01070303).
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 212 (Through 3 Years of Participation in NCT01070303).2145
SecondaryNumber of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 260 (4 Years of Participation in NCT01070303).

Clinical remission is defined as CDAI score \<150. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. A lower score indicates less severe Crohn's disease activity.

Time frame:
Week 260
Reported as:
Number · Participants
Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 260 (4 Years of Participation in NCT01070303).
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Clinical Remission (CDAI < 150 Points) at Week 260 (4 Years of Participation in NCT01070303).821
SecondaryNumber of Participants Achieving CR-100 at Week 104 (1 Year of Participation in NCT01070303)

A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

Time frame:
From Baseline of lead-in study to Week 104
Reported as:
Number · Participants
Number of Participants Achieving CR-100 at Week 104 (1 Year of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving CR-100 at Week 104 (1 Year of Participation in NCT01070303)2887
SecondaryNumber of Participants Achieving CR-100 at Week 152 (2 Years of Participation in NCT01070303)

A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

Time frame:
From Baseline of lead-in study to Week 152
Reported as:
Number · Participants
Number of Participants Achieving CR-100 at Week 152 (2 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving CR-100 at Week 152 (2 Years of Participation in NCT01070303)2874
SecondaryNumber of Participants Achieving CR-100 at Week 212 (3 Years of Participation in NCT01070303)

A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

Time frame:
From Baseline of lead-in study to Week 212
Reported as:
Number · Participants
Number of Participants Achieving CR-100 at Week 212 (3 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving CR-100 at Week 212 (3 Years of Participation in NCT01070303)2358
SecondaryNumber of Participants Achieving CR-100 at Week 260 (4 Years of Participation in NCT01070303)

A CR-100 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 100 or more points, indicating significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

Time frame:
From Baseline of lead-in study to Week 260
Reported as:
Number · Participants
Number of Participants Achieving CR-100 at Week 260 (4 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving CR-100 at Week 260 (4 Years of Participation in NCT01070303)827
SecondaryNumber of Participants Achieving CR-70 at Week 104 (1 Year of Participation in NCT01070303)

A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

Time frame:
Week 104
Reported as:
Number · Participants
Number of Participants Achieving CR-70 at Week 104 (1 Year of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving CR-70 at Week 104 (1 Year of Participation in NCT01070303)3192
SecondaryNumber of Participants Achieving CR-70 at Week 152 (2 Years of Participation in NCT01070303)

A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

Time frame:
From Baseline of lead-in Study to Week 152
Reported as:
Number · Participants
Number of Participants Achieving CR-70 at Week 152 (2 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving CR-70 at Week 152 (2 Years of Participation in NCT01070303)3077
SecondaryNumber of Participants Achieving CR-70 at Week 212 (3 Years of Participation in NCT01070303)

CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

Time frame:
From Baseline of lead-in study to Week 212
Reported as:
Number · Participants
Number of Participants Achieving CR-70 at Week 212 (3 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving CR-70 at Week 212 (3 Years of Participation in NCT01070303)2463
SecondaryNumber of Participants Achieving CR-70 at Week 260 (4 Years of Participation in NCT01070303)

A CR-70 is a decrease from Baseline of lead-in study (NCT00055523) in CDAI score of 70 or more points, indicating a significant improvement in disease severity. CDAI evaluates 8 Crohn's-related variables during a 1-week assessment period, yielding a composite score \>/= 0 and without upper limit. The range of scores during Study NCT01070303 was 0 to 464. Scores at Baseline of the lead-in study (NCT00055523), which were used to calculate clinical response, ranged from 201 to 450. A lower score indicates less severe Crohn's disease activity.

Time frame:
From Baseline of lead-in study to Week 260
Reported as:
Number · Participants
Number of Participants Achieving CR-70 at Week 260 (4 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving CR-70 at Week 260 (4 Years of Participation in NCT01070303)1027
SecondaryNumber of Participants Achieving Steroid-free Clinical Remission at Week 104 (1 Year of Participation in NCT01070303)

Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.

Time frame:
From Baseline of lead-in study to Week 104
Reported as:
Number · Participants
Number of Participants Achieving Steroid-free Clinical Remission at Week 104 (1 Year of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Steroid-free Clinical Remission at Week 104 (1 Year of Participation in NCT01070303)812
SecondaryNumber of Achieving Steroid-free Clinical Remission at Week 152 (2 Years of Participation in NCT01070303)

Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.

Time frame:
From Baseline of lead-in study to Week 152
Reported as:
Number · Participants
Number of Achieving Steroid-free Clinical Remission at Week 152 (2 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Achieving Steroid-free Clinical Remission at Week 152 (2 Years of Participation in NCT01070303)814
SecondaryNumber of Participants Achieving Steroid-free Clinical Remission at Week 212 (3 Years of Participation in NCT01070303)

Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.

Time frame:
From Baseline of lead-in study to Week 212
Reported as:
Number · Participants
Number of Participants Achieving Steroid-free Clinical Remission at Week 212 (3 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Steroid-free Clinical Remission at Week 212 (3 Years of Participation in NCT01070303)510
SecondaryNumber of Participants Achieving Steroid-free Clinical Remission at Week 260 (4 Years of Participation in NCT01070303)

Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free remission was achieved if the participant stopped taking corticosteroids before the visit and had a CDAI score \< 150 points at that visit.

Time frame:
From Baseline of lead-in study to Week 260
Reported as:
Number · Participants
Number of Participants Achieving Steroid-free Clinical Remission at Week 260 (4 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Steroid-free Clinical Remission at Week 260 (4 Years of Participation in NCT01070303)24
SecondaryNumber of Participants Achieving Steroid-free CR-100 at Week 104 (1 Year of Participation in NCT01070303)

Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.

Time frame:
From Baseline of lead-in study to Week 104
Reported as:
Number · Participants
Number of Participants Achieving Steroid-free CR-100 at Week 104 (1 Year of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Steroid-free CR-100 at Week 104 (1 Year of Participation in NCT01070303)915
SecondaryNumber of Participants Achieving Steroid-free CR-100 at Week 152 (2 Years of Participation in NCT01070303)

Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.

Time frame:
From Baseline of lead-in study to Week 152
Reported as:
Number · Participants
Number of Participants Achieving Steroid-free CR-100 at Week 152 (2 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Steroid-free CR-100 at Week 152 (2 Years of Participation in NCT01070303)915
SecondaryNumber of Participants Achieving Steroid-free CR-100 at Week 212 (3 Years of Participation in NCT01070303)

Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.

Time frame:
From Baseline of lead-in study to Week 212
Reported as:
Number · Participants
Number of Participants Achieving Steroid-free CR-100 at Week 212 (3 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Steroid-free CR-100 at Week 212 (3 Years of Participation in NCT01070303)612
SecondaryNumber of Participants Achieving Steroid-free CR-100 at Week 260 (4 Years of Participation in NCT01070303)

Among participants who were taking systemic corticosteroids at Baseline of the lead-in study (NCT00055523), steroid-free CR-100 was achieved if the participant stopped taking steroids before the visit and had a decrease from Baseline in CDAI score of 100 or more points at that visit.

Time frame:
From Baseline of lead-in study to Week 260
Reported as:
Number · Participants
Number of Participants Achieving Steroid-free CR-100 at Week 260 (4 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Steroid-free CR-100 at Week 260 (4 Years of Participation in NCT01070303)25
SecondaryChanges in Inflammatory Bowel Disease Questionnaire (IBDQ) Scores

IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period. It has 32 questions about bowel function and related symptoms, and their social and emotional impact. For each question, participants selected 1 of 7 responses, where 1=poor quality of life (e.g., feeling of fatigue "all of the time") and 7=good quality on the item (e.g., feeling of fatigue "none of the time"). IBDQ scores range from 32 to 224. Higher scores indicate better quality of life, and increases in IBDQ indicate improved overall quality of life.

Time frame:
Change from Baseline of lead-in study at Weeks 104, 152, 200, and 248
Reported as:
Mean · Scores on a scale
Changes in Inflammatory Bowel Disease Questionnaire (IBDQ) Scores
Scores on a scaleChange From Baseline-Week 104Change From Baseline-Week 152Change From Baseline-Week 200Change From Baseline-Week 248
Changes in Inflammatory Bowel Disease Questionnaire (IBDQ) Scores42.4 ± 36.2747.9 ± 33.7051.0 ± 32.7751.7 ± 32.67
SecondaryNumber of Participants Achieving Fistula Remission at Week 104 (1 Year of Participation in NCT01070303)

A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.

Time frame:
From Baseline of lead-in study to Week 104
Reported as:
Number · Participants
Number of Participants Achieving Fistula Remission at Week 104 (1 Year of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Fistula Remission at Week 104 (1 Year of Participation in NCT01070303)111
SecondaryNumber of Participants Achieving Fistula Remission at Week 152 (2 Years of Participation in NCT01070303)

A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.

Time frame:
From Baseline of lead-in study to Week 152
Reported as:
Number · Participants
Number of Participants Achieving Fistula Remission at Week 152 (2 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Fistula Remission at Week 152 (2 Years of Participation in NCT01070303)211
SecondaryNumber of Participants Achieving Fistula Remission at Week 212 (3 Years of Participation in NCT01070303)

A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.

Time frame:
From Baseline of lead-in study to Week 212
Reported as:
Number · Participants
Number of Participants Achieving Fistula Remission at Week 212 (3 Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Fistula Remission at Week 212 (3 Years of Participation in NCT01070303)110
SecondaryNumber of Participants Achieving Fistula Remission at Week 260 (Years of Participation in NCT01070303)

A count of the number of cutaneous fistulas draining upon gentle compression was performed at Baseline of the lead-in study (NCT00055523) and at study visits. Among participants with draining fistulas at Baseline of NCT00055523, a participant was considered to have achieved fistula remission at a study visit if the participant had no draining cutaneous fistulas at that visit.

Time frame:
From Baseline of lead-in study to Week 260
Reported as:
Number · Participants
Number of Participants Achieving Fistula Remission at Week 260 (Years of Participation in NCT01070303)
ParticipantsRemittersNon-Remitters
Number of Participants Achieving Fistula Remission at Week 260 (Years of Participation in NCT01070303)26

Adverse events

Collected over Treatment-emergent adverse events (AEs), defined as AEs beginning on or after first dose of adalimumab (in NCT00055523, NCT00055497, or NCT01070303) are reported. Treatment-emergent AEs were recorded up to 70 days after last dose of adalimumab.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Remitters—6/55 (10.9%)50/55 (90.9%)
Non-Remitters—69/221 (31.2%)207/221 (93.7%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventRemittersNon-Remitters
Crohn's diseaseGastrointestinal disorders0/5517/221
Small intestinal obstructionGastrointestinal disorders0/558/221
Coronary artery diseaseCardiac disorders1/551/221
Colonic stenosisGastrointestinal disorders1/551/221
ConstipationGastrointestinal disorders1/550/221
Ileal stenosisGastrointestinal disorders1/553/221
Intestinal obstructionGastrointestinal disorders1/551/221
Small intestinal stenosisGastrointestinal disorders1/553/221
PneumoniaInfections and infestations1/550/221
Back painMusculoskeletal and connective tissue disorders1/550/221
Most frequent other events
Showing 10 of 69
Most frequent other events
EventRemittersNon-Remitters
Crohn's diseaseGastrointestinal disorders23/5570/221
NasopharyngitisInfections and infestations15/5550/221
NauseaGastrointestinal disorders8/5551/221
Abdominal painGastrointestinal disorders12/5542/221
HeadacheNervous system disorders8/5547/221
ArthralgiaMusculoskeletal and connective tissue disorders8/5543/221
Injection site irritationGeneral disorders9/5521/221
DiarrhoeaGastrointestinal disorders8/5536/221
SinusitisInfections and infestations6/5534/221
PyrexiaGeneral disorders5/5533/221

Baseline characteristics

Age Continuous
Age Continuous(years)RemittersNon-RemittersTotal
Mean35.5 ± 10.8838.9 ± 12.5338.1 ± 12.19
Sex: Female, Male
Sex: Female, Male(Participants)RemittersNon-RemittersTotal
Female266086
Male197291
Region of Enrollment
Region of Enrollment(participants)RemittersNon-RemittersTotal
United States45132177
08

Study locations

43 sites
  • Gastroenterology Associates of the East Bay
    Berkeley, California 94705, United States
  • Long Beach Gastroenterology Assoc.
    Long Beach, California 90806, United States
  • Sharp Rees-Stealy Medical Group
    San Diego, California 92123, United States
  • Gastroenterology Assoc. of Fairfield Co.
    Bridgeport, Connecticut 06606, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Wake Research Associates
    Weston, Florida 33331, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Atlanta Gastroenterology Assoc.
    Atlanta, Georgia 30342, United States
  • Southeastern Digestive & Liver Disease
    Savannah, Georgia 31404, United States
  • Northwest Gastroenterologists, S.C.
    Arlington Heights, Illinois 60005, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Drug Research Services, Inc.
    Metairie, Louisiana 70001, United States
  • LSU School of Medicine
    New Orleans, Louisiana 70115, United States
  • Digestive Disorders Associates
    Annapolis, Maryland 21401, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Clinical Pharmacology Study Group
    Worchester, Massachusetts 01610, United States
  • Mayo Clinic and Mayo Foundation
    Rochester, Minnesota 55905, United States
  • Gastroenterology and Hepatology
    Kansas City, Missouri 64131, United States
  • Glenn Gordon, MD
    Mexico, Missouri 65265, United States
  • Deaconess Billings Clinic Research Division
    Billings, Montana 59101, United States
  • Gastroenterology Specialties, P.C.
    Lincoln, Nebraska 68503, United States
  • Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • NY Center for Clinical Research
    Lake Success, New York 11042, United States
  • New York Presbyterian Hospital
    New York, New York 10021, United States
  • Daniel Present
    New York, New York 10029, United States
  • Rochester Institute for Digestive Diseases
    Rochester, New York 14607, United States
  • UNC School of Medicine
    Chapel Hill, North Carolina 27599, United States
  • Charlotte Gastroenterology and Hepatology
    Charlotte, North Carolina 28207, United States
  • Carolina Research Associates
    Charlotte, North Carolina 28262, United States
  • Digestive Health Specialists
    Winston-Salem, North Carolina 27103, United States
  • Consultants for Clinical Research
    Cincinnati, Ohio 45219, United States
  • Oklahoma Foundation for Digestive Disease
    Oklahoma City, Oklahoma 73104, United States
  • Research Solutions
    Tulsa, Oklahoma 74104, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Peter Molloy, MD
    Pittsburgh, Pennsylvania 15224, United States
  • Diseases of the Digestive System
    Chattanooga, Tennessee 37421, United States
  • Nashville Medical Research Institute
    Nashville, Tennessee 37205, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22902, United States
  • Northwest Gastroenterology
    Bellevue, Washington 98004, United States
  • Inland Empire Gastroenterology
    Spokane, Washington 99204, United States
  • Tacoma Digestive Disease Center
    Tacoma, Washington 98405, United States
  • Wisconsin Center for Advanced Research
    Milwaukee, Wisconsin 53207, United States
09

References and documents

Publications

  • Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. Am J Clin Dermatol. 2018 Jun;19(3):437-447. doi: 10.1007/s40257-017-0341-6. PubMed 29380251 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2002, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2010
First posted
Feb 18, 2010
Start
Aug 2002
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
May 7, 2010
Last update
Apr 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01070303
Lead sponsor
Abbott
First posted
Feb 18, 2010
Start date
Aug 2002
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
May 7, 2010
Last update
Apr 11, 2011

Study contacts

Anne Camez, MD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion